Articles
On November 15, 2019, the FDA approved crizanlizumab (Adakveo; Novartis) to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged ≥16 years with sickle-cell disease.
Read More ›- Calquence Receives FDA Approval for the Treatment of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Despite Some Positive Trends, Report Confirms Lung Cancer Remains the Deadliest Form of Cancer
There have been significant improvements in the survival of patients with metastatic colorectal cancer (mCRC) over the past decade. However, patients with the disease who fail to respond to first- or second-line therapies, including chemotherapy and monoclonal antibodies, have few treatment options. Advances in subsequent treatment lines rather than in first- or second-line therapies now drive improvements in survival for these patients.
Read More ›- Teva Will Resume Production of Vincristine in Response to Shortage
- FDA Fast-Tracks Opdivo plus Yervoy Regimen for Treatment of Advanced Liver Cancer
- FDA Grants Accelerated Approval to Brukinsa for Patients with Mantle-Cell Lymphoma
By Chase Doyle
New research sponsored by the National Cancer Institute showed that patients with Medicaid or with no insurance had significantly worse overall survival in clinical trials compared with commercially insured patients. Read More ›
- FDA Approves Ziextenzo, Third Biosimilar to Pegfilgrastim for Febrile Neutropenia
- Trump Will Nominate Dr Hahn as Next FDA Commissioner
- Researchers Report High Rates of E-Cigarette Use Among Children and Teens
The November issue of The Oncology Pharmacist features important news and insights for today’s oncology pharmacists. Read More ›
Diagnosis of cholangiocarcinoma (CCA) is often identified at a late stage. Analyzing the tumorspecific mutation profile of a patient with CCA can improve the diagnosis and treatment for the individual patient. Read More ›
By Chase Doyle
Patient-centered clinical pathways may hold the promise of truly personalized medicine, improving value-based care and clinical outcomes. Read More ›
By Phoebe Starr
Treatment with the immune checkpoint inhibitor pembrolizumab (Keytruda) dramatically improved 5-year survival for patients with advanced non–small-cell lung cancer (NSCLC) compared with expected survival in the preimmunotherapy era. Read More ›